Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Less than $10/month! Screen on your Watchlists and Portfolios with Barchart Plus. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or

Zogenix Inc (ZGNX)

Zogenix Inc (ZGNX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 1,500,136
  • Shares Outstanding, K 56,227
  • Annual Sales, $ 81,690 K
  • Annual Income, $ -227,410 K
  • 60-Month Beta 0.89
  • Price/Sales 18.07
  • Price/Cash Flow N/A
  • Price/Book 8.35
Trade ZGNX with:
  • Price/Earnings ttm 0.00
  • Earnings Per Share ttm -4.27
  • Most Recent Earnings $-0.98 on 02/28/22
  • Next Earnings Date 02/24/22
  • Annual Dividend & Yield 0.00 (0.00%)
  • Most Recent Dividend N/A on N/A
  • Sectors:

Analyst Rating / Earnings Estimates

Current Rating
See More
Moderate Buy
Based on 6 analysts offering recommendations.
Earnings Estimates - Current Qtr 03/31/22
See More
  • Average Estimate -0.86
  • Number of Estimates 2
  • High Estimate -0.81
  • Low Estimate -0.90
  • Prior Year -1.00
  • Growth Rate Est. (year over year) +14.00%

Price Performance

See More
Period Period Low Period High Performance
1-Month
26.07 +2.34%
on 02/28/22
26.90 -0.82%
on 03/04/22
+0.59 (+2.26%)
since 02/04/22
3-Month
11.70 +128.03%
on 12/06/21
26.90 -0.82%
on 03/04/22
+14.83 (+125.15%)
since 12/03/21
52-Week
11.03 +141.89%
on 11/30/21
26.90 -0.82%
on 03/04/22
+6.42 (+31.69%)
since 03/04/21

Most Recent Stories

More News
Zogenix To Present New Long-term Data on FINTEPLA® (fenfluramine) in Lennox-Gastaut Syndrome (LGS) at AAN 2022

Two podium and one poster presentation share important new findings on FINTEPLA’s safety profile and its impact on non-seizure related benefits for LGS...

ZGNX : 26.68 (+1.60%)
Zogenix Provides Corporate Update and Reports Fourth Quarter and Full-Year 2021 Financial Results

Total revenue of $26.6 million in the fourth quarter and $81.7 million for the full yearFINTEPLA® net product sales of $23.5 million in the fourth quarter...

ZGNX : 26.68 (+1.60%)
Zogenix Supports New No-Cost Genetic Testing Program with United Mitochondrial Disease Foundation to Improve Diagnosis of Mitochondrial Diseases

Symptoms of mitochondrial diseases, such as Thymidine Kinase 2 deficiency (TK2d), can vary widely and mimic other rare and common diseases, making...

ZGNX : 26.68 (+1.60%)
Why Zogenix Flew Higher Before Leveling Off This Week

The company attracts a determined suitor from abroad.

ZGNX : 26.68 (+1.60%)
UCBJF : 179.0500 (+0.31%)
Zogenix (ZGNX) Stock Investigation: Halper Sadeh LLP Announces Investigation Into Whether the Sale of Zogenix, Inc. Is Fair to Shareholders; Investors Are Encouraged to Contact the Firm – ZGNX

Halper Sadeh LLP, a global investor rights law firm, is investigating whether the sale of Zogenix, Inc. (NASDAQ: ZGNX) to UCB is fair to Zogenix shareholders. Under the terms of the agreement, UCB would...

ZGNX : 26.68 (+1.60%)
Why Zogenix Stock Is on Fire Today

A buyout deal is lighting a fire underneath the biotech's shares today.

ZGNX : 26.68 (+1.60%)
Pre-Market Brief: Stock Indexes Swing Higher on Q4 Earnings Optimism

Morning Markets March S&P 500 futures this morning recovered from a 4-week low in overnight trade and are up +0.40%. Optimism about Q4 corporate earnings results is helping to push stocks higher this...

MS : 99.30 (-0.54%)
BAC : 39.62 (+0.18%)
SOFI : 8.11 (-0.12%)
PG : 173.92 (-1.11%)
ZGNX : 26.68 (+1.60%)
FREY : 1.0900 (+0.93%)
USB : 45.18 (+1.12%)
OESX : 0.8500 (-0.12%)
CSCO : 50.57 (-0.08%)
LEN : 188.43 (-0.49%)
KBH : 86.62 (-0.15%)
TOL : 150.14 (-0.35%)
Zogenix Submits New Drug Application for FINTEPLA® (Fenfluramine) in Japan for the Treatment of Epileptic Seizures Associated with Dravet Syndrome

EMERYVILLE, Calif., Dec. 21, 2021 (GLOBE NEWSWIRE) -- Zogenix, a global biopharmaceutical company specializing in rare disease therapies, announced that...

ZGNX : 26.68 (+1.60%)
Zogenix Submits Type II Variation Application to the European Medicines Agency (EMA) to Expand the Use of FINTEPLA® (Fenfluramine) for the Treatment of Seizures Associated with Lennox-Gastaut Syndrome

EMERYVILLE, Calif., Dec. 20, 2021 (GLOBE NEWSWIRE) -- Zogenix (Nasdaq: ZGNX), a global biopharmaceutical company developing and commercializing rare...

ZGNX : 26.68 (+1.60%)
Zogenix Reports Granting of Inducement Awards

EMERYVILLE, Calif., Dec. 16, 2021 (GLOBE NEWSWIRE) -- Zogenix (NASDAQ: ZGNX) today announced that the compensation committee of the company’s board of...

ZGNX : 26.68 (+1.60%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 100% Buy with a Strongest short term outlook on maintaining the current direction.

Long term indicators fully support a continuation of the trend.

See More Share

Business Summary

Zogenix is a specialty biopharmaceutical company focused on developing therapies for patients with rare central nervous system conditions that have limited or no treatment options. The company is currently pursuing two therapies targeting the Dravet Syndrome and the Lennox-Gastaut Syndrome.

See More

Key Turning Points

3rd Resistance Point 27.27
2nd Resistance Point 27.09
1st Resistance Point 26.88
Last Price 26.68
1st Support Level 26.49
2nd Support Level 26.31
3rd Support Level 26.10

See More

52-Week High 26.90
Last Price 26.68
Fibonacci 61.8% 20.84
Fibonacci 50% 18.97
Fibonacci 38.2% 17.09
52-Week Low 11.03

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.

Free Barchart Webinar